{
    "label": "Eligibility Criteria for Wegovy™ (semaglutide)",
    "node_type": "fieldset",
    "children": [
        {
            "label": "Eligibility Criteria for Wegovy™ (semaglutide)",
            "outcome": "Authorization for Wegovy™ (semaglutide), may be approved when all of the criteria are met",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "Used with a reduced-calorie diet and increased physical activity for chronic weight management in adults.",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Initial body mass index (BMI) should be either:",
                    "node_type": "checkbox",
                    "node_value": false,
                    "children": [
                        {
                            "label": "≥30 kg/m2 (obese)",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)",
                            "node_type": "checkbox",
                            "node_value": false
                        }
                    ]
                },
                {
                    "label": "Wegovy will not be coadministered with other semaglutide-containing products or with any other GLP-1 receptor agonist",
                    "node_type": "checkbox",
                    "node_value": false
                }
            ]
        }
    ]
}